Biogen dodges a bullet in its controversial quest to gain an approval for their experimental Alzheimer’s drug aducanumab
David Knopman, a professor of neurology at the Mayo Clinic and a longtime expert on treating Alzheimer’s, was recused from his regular panel seat on the upcoming review of Biogen’s Alzheimer’s drug aducanumab by outside experts at the FDA. Regulators cited his role as a site investigator for one of the two late-stage studies on aducanumab.
But his experience in the trial didn’t persuade Knopman to support Biogen. Instead, he concluded that the drug won’t really help anyone, will hurt some and definitely will cost “enormous resources” if approved. Which Knopman — whose professional credentials include a run as chair of the Medical and Scientific Advisory Council at the Alzheimer’s Association — is completely opposed to.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
